Welcome to
Endpoints News’
manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Lotte Biologics has launched its ADC services
and it has
signed
its first contract with an unnamed clinical-stage Asian biotech, the company said Thursday. Lotte will make the asset at its new ADC factory at the Syracuse Bio Campus in New York.
Ypsomed is
divesting
its diabetes care business
for up to CHF 420 million ($508 million) to TecMed as it moves to focus to become a subcutaneous self-injection solutions business, the company said Tuesday. The transaction is expected to close in the second half of this year.
PCI Pharma Services is
acquiring
Ajinomoto Althea, a fill-finish CDMO subsidiary of Ajinomoto, the company said Thursday. The transaction is expected to close in May this year and expands PCI Pharma’s services for prefilled syringes to North America. Financial details were not disclosed.
Samsung Biologics pulled in KRW 1.3 trillion ($907 million)
in the first quarter of 2025, up compared to the KRW 947 billion ($660 million) reported from the first quarter of 2024, the CDMO
said
Wednesday. The CDMO noted it is continuing to pull in new customers, especially with the opening of its Plant 5 factory in April.
Catalent has secured a
contract
with clinical-stage biotech Silexion Therapeutics to manufacture its cancer candidate, dubbed SIL204, at its factory in Limoges, France, according to a Wednesday release.
The FDA has
approved
Ferring Pharmaceuticals’ facility in Parsippany, NJ, to make its gene therapy asset, called Adstilardrin, which is approved for BCG-unresponsive non-muscle invasive bladder cancer, according to a Thursday release. As a part of the approval, Ferring will receive $200 million from its partner Royalty Pharma who co-developed the gene therapy.